- Home
- DXCM vs WAT Comparison
DXCM vs WAT Comparison
Compare DXCM & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | WAT |
|---|---|---|
| Founded | 1999 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 22.5B |
| IPO Year | 2005 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DXCM | WAT |
|---|---|---|
| Price | $69.68 | $397.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 16 |
| Target Price | $86.86 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 4.5M | 518.5K |
| Earning Date | 02-12-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.75 | 3.82 |
| EPS | 1.80 | ★ 10.88 |
| Revenue | ★ $4,515,900,000.00 | $3,105,638,000.00 |
| Revenue This Year | $17.38 | $7.96 |
| Revenue Next Year | $12.76 | $6.32 |
| P/E Ratio | $38.90 | ★ $36.83 |
| Revenue Growth | ★ 14.21 | 6.90 |
| 52 Week Low | $54.11 | $275.05 |
| 52 Week High | $93.25 | $423.56 |
Technical Indicators
Market Signals| Indicator | DXCM | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 66.80 | 60.45 |
| Support Level | $65.19 | $373.54 |
| Resistance Level | $68.18 | $408.67 |
| Average True Range (ATR) | 1.51 | 7.15 |
| MACD | 0.17 | 1.05 |
| Stochastic Oscillator | 81.15 | 68.49 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.